Trial Profile
A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6 VALENT OspA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs VLA 15 (Primary)
- Indications Lyme disease
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms VALOR
- Sponsors Pfizer; Valneva
- 15 Feb 2024 According to a Valneva media release, reflects significant payments related to the Phase 3 Lyme disease study, for which Valnevas cost contributions are expected to be completed in the first half 2024.
- 20 Dec 2023 Planned End Date changed from 31 Dec 2025 to 22 Dec 2025.
- 20 Dec 2023 Planned primary completion date changed from 31 Dec 2025 to 22 Dec 2025.